Anti-angiogenic therapy: From laboratory to the patient

F. O. Ademuyiwa, G. W. Sledge

Research output: Contribution to journalReview articlepeer-review

Abstract

Angiogenesis, or new vessel formation, plays a key role in the process of tumor growth and metastasis in breast cancer. Recent large phase-III trials (E2100 and AVADO) demonstrate the clinical utility of bevacizumab in combination with front-line taxane-based chemotherapy in patients with metastatic breast cancer, leading to its recent approval in the United States and Europe. Several other anti-angiogenic strategies against vascular endothelial growth factor are in various phases of clinical development. This paper reviews the data on bevacizumab in metastatic breast cancer and other anti-angiogenic strategies on development in breast cancer.

Original languageEnglish
Article numbere4
JournalBreast Cancer Online
Volume12
Issue number2
DOIs
StatePublished - 2009

Keywords

  • Bevacizumab
  • Breast cancer
  • Tyrosine kinase inhibitor
  • VEGF

Fingerprint

Dive into the research topics of 'Anti-angiogenic therapy: From laboratory to the patient'. Together they form a unique fingerprint.

Cite this